

Vitamin D and all-cause mortality among adults in USA: findings from the National Health and Nutrition Examination Survey Linked Mortality Study

Earl S Ford,* Guixiang Zhao, James Tsai and Chaoyang Li

Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA

*Corresponding author. Centers for Disease Control and Prevention, 4770 Buford Highway, MS K67, Atlanta, GA 30341, USA. E-mail: eford@cdc.gov

Accepted 9 December 2010

Background Whether concentrations of vitamin D are related to mortality remains unresolved. Our objective was to examine the relationship between serum concentrations of 25-hydroxyvitamin D and all-cause mortality in a national sample of US adults.

Methods We used data from the National Health and Nutrition Examination Survey Mortality Study from 2001 to 2004 with mortality compiled through 2006. Mortality status was established through a match to the National Death Index.

Results Of the 7531 participants, 347 died. Median follow-up was 3.8 years. The mean unadjusted concentrations of vitamin D were 54.1 nmol/l (21.7 ng/ml) among participants who died and 60.7 nmol/l (24.3 ng/ml) among participants who survived ($P=0.002$). After adjustment for socio-demographic factors, the hazard ratios (HR) for all-cause mortality were 1.65 [95% confidence interval (CI): 95% CI: 1.13–2.40] for participants with a concentration <50 nmol/l (<20 ng/ml) and 1.02 (95% CI: 0.74–1.41) for participants with a concentration of 50 to <75 nmol/l (20 to <30 ng/ml) compared with participants who had a concentration of ≥ 75 nmol/l (≥ 30 ng/ml). After more extensive adjustment, the HRs were 1.28 (95% CI: 0.86–1.90) and 0.91 (95% CI: 0.63–1.33), respectively. The fully adjusted HR per 10 nmol/l of vitamin D was 0.93 (95% CI: 0.86–1.01). The HRs did not vary by gender ($P=0.80$) or among the three major racial or ethnic groups ($P=0.46$).

Conclusions Concentrations of vitamin D were weakly and inversely related to all-cause mortality in this sample of US adults.

Keywords Cohort studies, health surveys, mortality, vitamin D

Introduction

Historically, vitamin D is recognized for its critical role in maintaining calcium homeostasis and bone health. Over time, the extraskelatal effects of vitamin

D also emerged.^{1,2} Vitamin D is now thought to affect cell proliferation and differentiation,^{3–6} the immune system⁷ and renin/angiotensin system.^{8,9} Along with this new appreciation of the physiological effects of

vitamin D, evidence has also been accumulating suggesting that vitamin D affects the risk for morbidity and mortality from a growing list of chronic conditions including cardiovascular disease, cancer and diabetes.¹⁰

Major contributors to vitamin D status include exposure to sunshine, diet and the use of supplements.¹¹ Because of societal changes, many people do not receive enough sunshine to produce adequate amounts of vitamin D to ensure optimal health. Thus, the prevalence of low concentration of vitamin D in many populations including USA is high.^{12–14} Furthermore, there is evidence that low vitamin D status is worsening in USA.¹⁴

Because only a limited number of studies have examined the risks for all-cause mortality associated with low concentrations of vitamin D,^{15–26} our objective was to examine the relationship between circulating concentrations of 25-hydroxyvitamin D and all-cause mortality in a representative sample of adults in USA.

Methods

We used data from the mortality follow-up of adults aged ≥ 20 years who participated in the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2004. During the baseline surveys, a national sample was recruited using a multistage, stratified sampling design. The survey was designed to produce results representative of the civilian, non-institutionalized US population. The participants were interviewed at home and were invited to attend a mobile examination centre, where they were asked to complete additional questionnaires, to undergo various examinations, and to provide a blood sample. The study received human subjects' approval, and participants were asked to sign an informed consent form. Details about the survey may be found elsewhere.²⁷

Mortality for participants of the NHANES 2001–04 was ascertained through 31 December 2006 by linking participants' information to death certificate data contained in the National Death Index.²⁸ Participants who were not identified as having died were considered to be alive. A small number of participants ($N=18$) were considered ineligible for the study because of insufficient data to conduct the matching.

Serum concentrations of 25-hydroxyvitamin D were measured using the Diasorin 25-OH-Vitamin D assay, a radioimmunoassay. The coefficient of variation ranged from 4.4% to 13.2%.

Covariates included age, gender, race or ethnicity (white, African American, Mexican American, other Hispanic, mixed race), educational status (<high school, high school graduate and >high school), smoking status, alcohol consumption, leisure-time physical activity, dietary supplement use during the past month (yes/no), systolic blood pressure,

concentrations of high-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, concentrations of haemoglobin A1c (HbA1c), concentrations of C-reactive protein, concentrations of serum calcium, urinary albumin–creatinine ratio, waist circumference, 6-month time period when an examination was performed (1 May through 31 October and 1 November through 30 April) and physician-diagnosed cardiovascular disease, cancer and diagnosed diabetes (yes, no). Current smokers were defined as participants who had smoked ≥ 100 cigarettes during their lifetime and were still smoking. Former smokers were defined as participants who had smoked ≥ 100 cigarettes during their lifetime but had stopped. Participants who had smoked < 100 cigarettes during their lifetime were classified as never having smoked. The intake of alcohol (gram/day) was obtained from a single 24-h dietary recall. To estimate leisure-time physical activity, we summed the product of monthly time spent in each activity multiplied by the metabolic equivalent (MET) value for that activity yielding a MET-hours index. One MET is the energy expenditure of ~ 3.5 ml oxygen/kg body weight/min or 1 kcal/kg body weight/h. The use of vitamins, minerals and supplements was derived from the question 'Have you used or taken any vitamins, minerals or other dietary supplements in the past month?' Up to four blood pressure measurements were attempted from each participant. We used the average of the last two measurements for participants who had three measurements, the second one for participants with only two measurements and the one for participants who had one measurement. Concentrations of serum cholesterol and high-density lipoprotein cholesterol were measured enzymatically on a Hitachi 704 (Boehringer Mannheim Diagnostics, Indianapolis, IN, USA) using commercial reagents. Concentrations of C-reactive protein were measured by using latex-enhanced nephelometry (N High Sensitivity CRP assay) on a Nephelometer II Analyzer System (BN II) (Dade Behring Deerfield, IL, USA). Concentrations of HbA1c were measured with boronate affinity high-performance liquid chromatography using Primus CLC330 and Primus CLC385 instruments (Primus Corporation, Kansas City, MO, USA). Concentrations of serum calcium were measured by using colorimetry after reacting with *o*-cresolphthalein complexone in the presence of 8-hydroxyquinoline (Beckman Synchron LX20, Beckman Coulter Brea, CA, USA). Albumin was measured by using a solid-phase fluorescent immunoassay with a digital Sequoia-Turner model 450 Fluorometer (Sequoia-Turner Corp., Mountain View, CA, USA), and creatinine was measured by using a Jaffé rate reaction on a Beckman Synchron CX3 clinical analyzer (Beckman Instruments, Brea, CA, USA). The waist circumference was measured at the high point of the iliac crest at minimal respiration to the nearest 0.1 cm. Participants who responded

affirmatively to the question 'Have you ever been told by a doctor or health professional you have diabetes or sugar diabetes?' were considered to have diagnosed diabetes. Those who answered that they had not been told so or that they had borderline diabetes were not considered to have diagnosed diabetes. Participants were considered to have cardiovascular disease if they had ever been told by a doctor or other health professional that they had congestive heart failure, coronary heart disease, angina, heart attack or stroke. Participants were considered to have cancer if they had ever been told by a doctor or other health professional that they had cancer or a malignancy.

Differences in means and percentages were tested with *t*-tests and chi-squared tests, respectively. We used proportional hazard regression analysis to examine the independent association between concentrations of vitamin D and mortality. We examined vitamin D as a continuous variable as well as a categorical variable <50 nmol/l (<20 ng/ml = deficiency), 50 to <75 nmol/l (20 to <30 ng/ml = insufficiency) and ≥ 75 nmol/l (≥ 30 ng/ml = sufficiency). To account for the complex survey design, analyses were conducted with SUDAAN and sampling weights were used.

Results

Of the 11 595 participants who were eligible for the mortality study, 10 877 attended the mobile examination centre. After excluding pregnant women, 10 270 participants were left. Further exclusions for missing data reduced the sample to 7531 participants of whom 347 died (92 malignant neoplasms, 120 major cardiovascular disease and 135 other causes). The 7531 participants included 3867 men, 4089 whites, 1359 African Americans, 1554 Mexican Americans and 529 of another race or ethnicity. The median follow-up was 3.8 years.

In the analytic sample, the mean concentration of vitamin D was 60.6 nmol/l (24.3 ng/ml) [25th percentile: 43.3 nmol/l (17.4 ng/ml), 50th percentile: 57.9 nmol/l (23.2 ng/ml), 75th percentile: 73.2 nmol/l (29.3 ng/ml)]. The mean concentrations of vitamin D were 54.1 nmol/l (21.7 ng/ml) among participants who died and 60.7 nmol/l (24.3 ng/ml) among participants who survived ($P=0.002$). Furthermore, 31.5% of participants had a concentration <50 nmol/l (<20 ng/ml), 42.5% had a concentration 50 to <75 nmol/l (20 to <30 ng/ml) and 26.0% had a concentration ≥ 75 nmol/l (≥ 30 ng/ml).

Numerous differences in the unadjusted means or percentages of covariates across the three categories of concentrations of vitamin D existed (Table 1).

Concentrations of vitamin D modelled as a continuous variable predicted all-cause mortality in models that were adjusted for socio-demographic factors as well as lifestyle factors (Table 2). Once a series of

physiological factors were added, however, the regression coefficient lost statistical significance but did retain borderline significance in the final model that was also adjusted for several comorbidities. We did not find evidence that the risk estimates varied by gender ($P=0.80$) or among the three major racial or ethnic groups ($P=0.46$). In models that included concentrations of vitamin D categorized into three groups, participants who were deficient had an increased risk of mortality compared with participants who had sufficient concentrations. However, the inclusion of lifestyle behaviours and physiological variables attenuated the HRs to the extent that the 95% confidence interval (95% CI) included unity.

Discussion

Given the high prevalence of vitamin D deficiency and insufficiency in many populations and the existence of relative inexpensive and easy interventions to boost concentrations of vitamin D, supplementation with vitamin D to potentially reduce morbidity and mortality holds great appeal. Our results provide limited evidence that vitamin D is associated with reduced all-cause mortality. Only concentrations of vitamin D used as a continuous variable had some degree of predictive ability of all-cause mortality. Our analyses illustrate that adjustment for potential confounders can substantially affect the risk estimates and, therefore, the selection of potential confounders deserves careful consideration.

Several analyses of the NHANES III Mortality Study reported that low concentrations of vitamin D were associated with mortality from all causes and/or cardiovascular disease.^{17,18,23} Whereas several other studies have described inverse relationships between concentrations of vitamin D and all-cause mortality,^{19–22,24,26} some studies have not found concentrations of vitamin D to be an independent predictor of mortality from all causes or coronary heart disease.^{15,16,25} A meta-analysis of prospective studies found that the highest quintile of concentrations of vitamin D was associated with an elevated risk of mortality from cardiovascular disease.²⁹ Reductions in mortality from cancer, and particularly from colorectal cancer, have also been reported in prospective studies.^{30,31} An ecological analysis suggested that cancer mortality for 10 sites was inversely related to ultraviolet-B exposure.³²

An expanding body of literature examines the relationships between concentrations of vitamin D and the incidence of many chronic and acute conditions. We will restrict our brief summary of the emerging literature to cardiovascular disease, cancer and respiratory infections. A meta-analysis of four prospective studies found that participants with the lowest category of concentrations of vitamin D had an elevated risk of cardiovascular disease incidence.²⁹ However, another meta-analysis was more cautious

Table 1 Unadjusted baseline characteristics by category of serum concentration of vitamin D among 7531 participants aged ≥ 20 years, National Health and Nutrition Examination Survey Linked Mortality Study 2001–06

| Characteristics | Vitamin D concentration (nmol/l) | | | | | | P |
|---|----------------------------------|------|--------------------|------|--------------------|------|-------|
| | <50 (N=2983) | | 50 to <75 (N=3049) | | ≥ 75 (N=1489) | | |
| | % or mean | SE | % or mean | SE | % or mean | SE | |
| Men (%) | 44.9 | 1.0 | 53.4 | 1.1 | 49.6 | 1.7 | 0.04 |
| Whites (%) | 52.8 | 2.9 | 78.9 | 2.0 | 91.1 | 1.4 | <0.01 |
| High school graduate or higher (%) | 51.6 | 1.6 | 59.2 | 1.4 | 56.2 | 2.1 | 0.07 |
| Current smoker (%) | 28.5 | 1.2 | 22.9 | 1.0 | 24.9 | 1.6 | 0.06 |
| Vitamin, mineral or supplement use (%) | 40.0 | 1.1 | 57.7 | 1.4 | 63.0 | 1.4 | <0.01 |
| Urinary-albumin–creatinine ratio <30 g/g (%) | 88.4 | 0.8 | 92.3 | 0.4 | 94.5 | 0.8 | <0.01 |
| Cardiovascular disease (%) | 9.6 | 0.7 | 7.8 | 0.8 | 7.5 | 0.8 | 0.03 |
| Cancer (%) | 7.4 | 0.5 | 9.0 | 0.7 | 9.2 | 0.6 | 0.02 |
| Diabetes (%) | 9.4 | 0.6 | 6.3 | 0.5 | 4.7 | 0.8 | <0.01 |
| Age (years) | 45.3 | 0.4 | 46.6 | 0.5 | 45.6 | 0.5 | 0.56 |
| Alcohol intake (g/day) | 10.7 | 0.8 | 13.1 | 0.9 | 14.2 | 1.5 | 0.02 |
| Leisure-time physical activity (MET-h) | 53.0 | 3.6 | 79.5 | 3.9 | 105.6 | 7.3 | <0.01 |
| Systolic blood pressure (mmHg) | 124.5 | 0.4 | 122.5 | 0.4 | 120.0 | 0.7 | <0.01 |
| Non-high-density lipoprotein cholesterol (mmol/l) | 3.92 | 0.03 | 3.88 | 0.02 | 3.78 | 0.04 | 0.01 |
| High-density lipoprotein cholesterol (mmol/l) | 1.31 | 0.01 | 1.35 | 0.01 | 1.45 | 0.01 | <0.01 |
| HbA1c (%) | 5.6 | <0.1 | 5.5 | <0.1 | 5.4 | <0.1 | <0.01 |
| C-reactive protein (mg/l) | 5.1 | 0.3 | 3.6 | 0.1 | 3.5 | 0.2 | <0.01 |
| Serum calcium (mmol/l) | 2.4 | 0.0 | 2.4 | 0.0 | 2.4 | 0.0 | <0.01 |
| Waist circumference (cm) | 100.0 | 0.5 | 96.5 | 0.4 | 92.8 | 0.6 | <0.01 |
| Vitamin D (nmol/l) | 35.3 | 0.3 | 60.9 | 0.2 | 90.5 | 0.8 | <0.01 |

when it reported that only five of the nine prospective studies found inverse relationships between concentrations of vitamin D and incident cardiovascular disease.³³ Furthermore, the results from four trials did not yield conclusive evidence about a beneficial effect of supplementation with vitamin D on cardiovascular outcomes.³³ A series of meta-analyses based on prospective observational studies has concluded that concentrations of vitamin D are inversely related to breast cancer³⁴ and colorectal cancer^{35–37} but not prostate cancer.³⁸ A promising randomized trial found that supplementation with 1500 mg/day of calcium and 1100 IU/day of vitamin D₃ reduced cancer incidence by ~60%.³⁹ Clinical trials suggest that supplementation with vitamin D may reduce incident influenza, recurrent pneumonia and upper respiratory tract infections in children and young adults,^{40–42} and a prospective study suggests that concentrations of vitamin D were inversely associated with the incidence of upper respiratory tract infections in adults.⁴³

Supplementation studies provide mixed evidence concerning a beneficial effect of vitamin D on disease prevention or reduction in mortality. A meta-

analysis of 18 randomized controlled trials found that supplementation with vitamin D in amounts ranging from 300 to 2000 IU and a mean of 528 IU reduced mortality by 7% [risk ratio (RR)=0.93, 95% CI: 0.97–0.99].⁴⁴ Our estimate that a change in the serum concentration of vitamin D of 10 nmol/l equates to an approximate change of 6–7% in mortality is consistent with the estimated reduction in mortality from the meta-analysis assuming that an increase in the intake of vitamin D by 1000 IU/day increases the serum concentration of vitamin D by 15–25 nmol/l.⁴⁵ In two trials, however, vitamin D supplementation produced a 10% reduction in cardiovascular outcomes (RR=0.90, 95% CI: 0.77–1.05).⁴⁶

Because of the aforementioned health consequences of hypovitaminosis D, the high prevalence of vitamin D deficiency and insufficiency in USA is troublesome. Data from NHANES III showed that—depending on gender, race or ethnicity and age—from 8% to 76% of the participants had a concentration <49.9 nmol/l (<20 ng/ml).¹² Deficiency was particularly prominent among African American women. More recent national data suggested that the mean serum

Table 2 HRs (95% CI) for concentrations of vitamin D and all-cause mortality among 7531 participants aged ≥ 20 years, National Health and Nutrition Examination Survey Linked Mortality Study 2001–06

| Model | Vitamin D (nmol/l) | | | | | | | |
|-------------------------------|--------------------|------------------|-----------|--------------------------|---------------------------|---------------------------|-----------------------------|-------------------------------|
| | <50 | 50 to <75 | ≥ 75 | Quartile 1 (7 to <45) | Quartile 2 (45 to <60) | Quartile 3 (60 to <75) | Quartile 4 (≥ 75) | Continuous (per 10 nmol/l) |
| No. deaths/total ^a | 163/2983 | 127/3049 | 57/1499 | 127/2362 | 93/1962 | 70/1708 | 57/1499 | 347/7531 |
| Model 1 | 1.66 (1.16–2.37) | 1.03 (0.74–1.43) | 1.00 | 1.74 (1.18–2.58) | 1.24 (0.83–1.86) | 0.93 (0.66–1.33) | 1.00 | 0.89 (0.82–0.96) |
| Model 2 | 1.65 (1.13–2.40) | 1.02 (0.74–1.41) | 1.00 | 1.74 (1.15–2.64) | 1.25 (0.84–1.85) | 0.92 (0.65–1.29) | 1.00 | 0.89 (0.81–0.97) |
| Model 3 | 1.46 (0.97–2.19) | 0.99 (0.71–1.37) | 1.00 | 1.57 (1.01–2.44) | 1.20 (0.80–1.80) | 0.90 (0.63–1.27) | 1.00 | 0.91 (0.84–<1.00) |
| Model 4 | 1.26 (0.85–1.88) | 0.93 (0.65–1.31) | 1.00 | 1.39 (0.89–2.17) | 1.13 (0.76–1.69) | 0.85 (0.59–1.23) | 1.00 | 0.94 (0.86–1.01) |
| Model 5 | 1.28 (0.86–1.90) | 0.91 (0.63–1.33) | 1.00 | 1.39 (0.90–2.14) | 1.12 (0.77–1.64) | 0.83 (0.56–1.22) | 1.00 | 0.93 (0.86–1.01) |

Model 1 is adjusted for age and 6-month examination period.

Model 2 is adjusted for age, gender, race or ethnicity, educational status and 6-month examination period.

Model 3 is adjusted for age, gender, race or ethnicity, educational status, smoking status, alcohol intake, leisure-time physical activity, vitamin or mineral or supplement use and 6-month examination period.

Model 4 is adjusted for age, gender, race or ethnicity, educational status, smoking status, alcohol intake, leisure-time physical activity, vitamin or mineral or supplement use, systolic blood pressure, non-high-density lipoprotein cholesterol, high-density lipoprotein cholesterol, HbA1c, C-reactive protein, albuminuria, serum calcium, waist circumference and 6-month examination period.

Model 5 is adjusted for age, gender, race or ethnicity, educational status, smoking status, alcohol intake, leisure-time physical activity, vitamin or mineral or supplement use, systolic blood pressure, non-high-density lipoprotein cholesterol, high-density lipoprotein cholesterol, HbA1c, C-reactive protein, albuminuria, serum calcium, waist circumference, histories of cardiovascular disease, cancer and diabetes, and 6-month examination period.

^aUnweighted numbers.

concentrations of vitamin D in the US population had declined.¹⁴ Increased body mass index, decreased consumption of milk and increased sun protection appeared to correlate with the decrease in vitamin D.

In USA, the recommended daily allowance for vitamin D in 2010 ranges from 600 to 800 IU/day.⁴⁷ During 2005–06, the percentage of adults surpassing the adequate intake ranged from <3% to 45% of male adults and from <3% to 32% of female adults.⁴⁸ However, various experts have proposed that increased intakes of vitamin D are necessary to maximize health.^{49–52} Although optimal circulating concentrations of vitamin D remain under discussion, people with a great deal of sun exposure have concentrations in the range of ~ 120 – 175 nmol/l.⁵³ To achieve such concentrations through the oral route requires amounts of vitamin D generally above current recommendations.^{54–59}

Although the prospective design and the representative sample of US adults are positive attributes of our study, several limitations should be considered as well. First, the follow-up of our study with a mean of ~ 4 years was relatively short. Thus, a limited number of deaths accrued. Nevertheless, our study included a higher number of deaths than several other studies. For outcomes such as cancer that generally have long incubation times, studies of limited duration may be especially problematical. Because blood concentrations of vitamin D reflect behaviours that include exposure to sunshine as well as intakes from diet and supplements, blood concentrations of vitamin D may be a risk marker rather than a risk factor for mortality. Adequate concentrations of vitamin D may reflect a pattern of behaviour to minimize threats to one's health that may include taking supplements with vitamin D. Although we controlled for numerous potential confounders, we may not have included all relevant ones and, therefore, residual confounding remains a distinct possibility. We were unable to include concentrations of parathyroid hormone in our analyses because this hormone was not assessed during the calendar years included in our study. In addition, we were unable to fully adjust for seasonality and geographical location because these data were not available. Only a single measurement of vitamin D was available. Had more such measurements been available, the vitamin D status of each participant and the relationships between concentrations of vitamin D and mortality could have been assessed with increased accuracy. Finally, laboratory drift may have affected the measurements of vitamin D in our sample.⁶⁰ However, an analysis that compared various statistics based on the original data from 2000 to 2004 and on a truncated set of data found only small differences.⁶¹

In conclusion, our study provides limited support for an inverse relationship between concentrations of vitamin D and all-cause mortality. Future monitoring of this cohort will provide additional opportunities to

link vitamin D status to mortality with larger numbers of events and longer duration of follow-up. Because some evidence has shown a benefit of adequate vitamin D status on morbidity and mortality, the high prevalence of vitamin D deficiency and insufficiency and the availability of an inexpensive and readily accessible remedy, it is imperative to clarify the relationships between vitamin D status and morbidity and mortality. The potential impact of adequate vitamin D status is illustrated by a study that suggested that, by supplementing adults in the United States with 1000 IU/day, economic costs from vitamin

D-associated conditions could be reduced by ~\$16 to \$25 billion.⁶²

Acknowledgement

The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Conflict of interest: None declared.

KEY MESSAGES

- Observational studies yield inconclusive evidence about the relationship between circulating concentrations of vitamin D and all-cause mortality.
- In a national sample of adults aged ≥ 20 years from USA, adults with a concentration of vitamin D < 50 nmol/l had a moderately increased risk for all-cause mortality compared with adults with a concentration of vitamin D ≥ 75 nmol/l after adjustment for demographic variables (adjusted HR = 1.65, 95% CI: 1.13–2.40).
- After more extensive adjustment with lifestyle factors and physiological, biochemical and anthropometric variables, the HR was substantially attenuated (adjusted HR = 1.26, 95% CI: 0.85–1.88).
- The role of possible confounding in the relationship between concentrations of vitamin D and health outcomes such as all-cause mortality requires careful consideration.

References

- 1 Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? *Int J Epidemiol* 1980;**9**:227–31.
- 2 Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. *Int J Epidemiol* 1981;**10**:337–41.
- 3 Birge SJ, Alpers DH. Stimulation of intestinal mucosal proliferation by vitamin D. *Gastroenterology* 1973;**64**: 977–82.
- 4 Matsui T, Nakao Y, Kobayashi N *et al*. Phenotypic differentiation-linked growth inhibition in human leukemia cells by active vitamin D3 analogues. *Int J Cancer* 1984;**33**:193–202.
- 5 Yoshida M, Ishizuka S, Hoshi A. Biological activity of vitamin D3 derivatives in inducing differentiation of HL-60 human promyelocytic leukemia cells. *J Pharmacobiodyn* 1984;**7**:962–68.
- 6 Mohtai M, Yamamoto T. Smooth muscle cell proliferation in the rat coronary artery induced by vitamin D. *Atherosclerosis* 1987;**63**:193–202.
- 7 Hewison M. Vitamin D and the immune system: new perspectives on an old theme. *Endocrinol Metab Clin North Am* 2010;**39**:365–79.
- 8 Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002;**110**:229–38.
- 9 Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. *Hypertension* 2010;**55**:1283–88.
- 10 Zittermann A, Gummert JF, Bergermann J. Vitamin D deficiency and mortality. *Curr Opin Clin Nutr Metab Care* 2009;**12**:634–39.
- 11 Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;**357**: 266–81.
- 12 Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone* 2002;**30**:771–77.
- 13 Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. *Ethn Dis* 2005;**15**:S5–101.
- 14 Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. *Am J Clin Nutr* 2008;**88**:1519–27.
- 15 Sambrook PN, Chen JS, March LM *et al*. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: a cohort study. *J Clin Endocrinol Metab* 2004;**89**: 5477–81.
- 16 Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. *Am J Clin Nutr* 2006;**84**:616–22.
- 17 Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality

- in the general population. *Arch Intern Med* 2008;**168**:1629–37.
- ¹⁸ Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. *J Am Geriatr Soc* 2009;**57**:1595–603.
- ¹⁹ Kilkkinen A, Knekt P, Aro A *et al*. Vitamin D status and the risk of cardiovascular disease death. *Am J Epidemiol* 2009;**170**:1032–39.
- ²⁰ Kuroda T, Shiraki M, Tanaka S, Ohta H. Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. *Bone* 2009;**44**:168–72.
- ²¹ Pilz S, Dobnig H, Nijpels G *et al*. Vitamin D and mortality in older men and women. *Clin Endocrinol* 2009;**71**:666–72.
- ²² Semba RD, Houston DK, Ferrucci L *et al*. Low serum 25-hydroxyvitamin D concentrations are associated with greater all-cause mortality in older community-dwelling women. *Nutr Res* 2009;**29**:525–30.
- ²³ Fiscella K, Franks P. Vitamin D, race, and cardiovascular mortality: findings from a national US sample. *Ann Fam Med* 2010;**8**:11–18.
- ²⁴ Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Tromso study. *Eur J Endocrinol* 2010;**162**:935–42.
- ²⁵ Cawthon PM, Parimi N, Barrett-Connor E *et al*. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. *J Clin Endocrinol Metab* 2010;**95**:4625–34.
- ²⁶ Virtanen JK, Nurmi T, Voutilainen S, Mursu J, Tuomainen TP. Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. *Eur J Nutr* 2010. [Epub ahead of print 26 October 2010] PubMed PMID: 20976461.
- ²⁷ Centers for Disease Control and Prevention. *National Health and Nutrition Examination Survey*. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm (30 December 2010, date last accessed).
- ²⁸ Centers for Disease Control and Prevention. *NHANES (1999–2004) Linked Mortality Files*. http://www.cdc.gov/nchs/data_access/data_linkage/mortality/nhanes_99_04_linkage.htm (30 December 2010, date last accessed).
- ²⁹ Grandi NC, Breitling LP, Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. *Prev Med* 2010;**51**:228–33.
- ³⁰ Giovannucci E, Liu Y, Rimm EB *et al*. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. *J Natl Cancer Inst* 2006;**98**:451–59.
- ³¹ Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. *J Natl Cancer Inst* 2007;**99**:1594–602.
- ³² Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. *BMC Cancer* 2006;**6**:264.
- ³³ Pittas AG, Chung M, Trikalinos T *et al*. Systematic review: vitamin D and cardiometabolic outcomes. *Ann Intern Med* 2010;**152**:307–14.
- ³⁴ Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. *Eur J Cancer* 2010;**46**:2196–205.
- ³⁵ Gorham ED, Garland CF, Garland FC *et al*. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. *Am J Prev Med* 2007;**32**:210–16.
- ³⁶ Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E. Vitamin D and prevention of colorectal adenoma: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2008;**17**:2958–69.
- ³⁷ Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. *Aliment Pharmacol Ther* 2009;**30**:113–25.
- ³⁸ Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. *Cancer Epidemiol* 2009;**33**:435–45.
- ³⁹ Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr* 2007;**85**:1586–91.
- ⁴⁰ Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr* 2010;**91**:1255–60.
- ⁴¹ Laaksi I, Ruohola JP, Mattila V, Auvinen A, Ylikomi T, Pihlajamaki H. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. *J Infect Dis* 2010;**202**:809–14.
- ⁴² Manaseki-Holland S, Qader G, Isaq MM *et al*. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. *Trop Med Int Health* 2010;**15**:1148–55.
- ⁴³ Sabetta JR, DePettillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. *PLoS One* 2010;**5**:e11088.
- ⁴⁴ Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. *Arch Intern Med* 2007;**167**:1730–37.
- ⁴⁵ Grant WB, Schuitmaker GE. Health benefits of higher serum 25-hydroxyvitamin D levels in The Netherlands. *J Steroid Biochem Mol Biol* 2010;**121**:456–58.
- ⁴⁶ Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. *Ann Intern Med* 2010;**152**:315–23.
- ⁴⁷ Institute of Medicine. *Dietary Reference Intakes for Calcium and Vitamin D*. <http://www.iom.edu/~media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Report%20Brief.pdf> (30 December 2010, date last accessed).
- ⁴⁸ Moshfegh A, Goldman J, Ahuja J, Rhodes D, LaComb R. *What We Eat in America, NHANES 2005–2006: Usual Nutrient Intakes from Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus, and Magnesium*. http://www.ars.usda.gov/SP2UserFiles/Place/12355000/pdf/0506/usual_nutrient_intake_vitD_ca_phos_mg_2005-06.pdf (30 December 2010, date last accessed).
- ⁴⁹ Heaney RP. The vitamin D requirement in health and disease. *J Steroid Biochem Mol Biol* 2005;**97**:13–19.
- ⁵⁰ Vieth R, Bischoff-Ferrari H, Boucher BJ *et al*. The urgent need to recommend an intake of vitamin D that is effective. *Am J Clin Nutr* 2007;**85**:649–50.

- ⁵¹ Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. *Expert Opin Pharmacother* 2008;**9**:107–18.
- ⁵² Whiting SJ, Calvo MS. Correcting poor vitamin D status: do older adults need higher repletion doses of vitamin D3 than younger adults? *Mol Nutr Food Res* 2010;**54**:1077–84.
- ⁵³ Vieth R. What is the optimal vitamin D status for health? *Prog Biophys Mol Biol* 2006;**92**:26–32.
- ⁵⁴ Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. *Nutr J* 2004;**3**:8.
- ⁵⁵ Aloia JF, Patel M, Dimaano R *et al*. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. *Am J Clin Nutr* 2008;**87**:1952–58.
- ⁵⁶ Cashman KD, Hill TR, Lucey AJ *et al*. Estimation of the dietary requirement for vitamin D in healthy adults. *Am J Clin Nutr* 2008;**88**:1535–42.
- ⁵⁷ Cashman KD, Wallace JM, Horigan G *et al*. Estimation of the dietary requirement for vitamin D in free-living adults ≥ 64 y of age. *Am J Clin Nutr* 2009;**89**:1366–74.
- ⁵⁸ Dong Y, Stallmann-Jorgensen IS, Pollock NK *et al*. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. *J Clin Endocrinol Metab* 2010;**95**:4584–91.
- ⁵⁹ Schwalfenberg GK, Genuis SJ. Vitamin D supplementation in a nursing home population. *Mol Nutr Food Res* 2010;**54**:1072–76.
- ⁶⁰ Centers for Disease Control and Prevention. *Analytical Note for NHANES 2000-2006 and NHANES III (1988-1994) 25-Hydroxyvitamin D Analysis*. http://www.cdc.gov/nchs/data/nhanes/nhanes3/VitaminD_analyticnote.pdf (30 December 2010, date last accessed).
- ⁶¹ Looker AC, Lacher DA, Pfeiffer CM, Schleicher RL, Picciano MF, Yetley EA. Data advisory with regard to NHANES serum 25-hydroxyvitamin D data. *Am J Clin Nutr* 2009;**90**:695.
- ⁶² Grant WB, Garland CF, Gorham ED. An estimate of cancer mortality rate reductions in Europe and the US with 1,000 IU of oral vitamin D per day. *Recent Results Cancer Res* 2007;**174**:225–34.